Is Alzamend Neuro Stock a good buy in 2025, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NASDAQ: ALZN) stock is to Buy ALZN stock.
Out of 1 analyst, 0 (0%) are recommending ALZN as a Strong Buy, 1 (100%) are recommending ALZN as a Buy, 0 (0%) are recommending ALZN as a Hold, 0 (0%) are recommending ALZN as a Sell, and 0 (0%) are recommending ALZN as a Strong Sell.
What is ALZN's earnings growth forecast for 2026-2026?
(NASDAQ: ALZN) Alzamend Neuro's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 31.84%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 65.68%.
Alzamend Neuro's earnings in 2025 is -$4,280,588.
In 2026, ALZN is forecast to generate -$11,149,787 in earnings, with the lowest earnings forecast at -$11,149,787 and the highest earnings forecast at -$11,149,787.
What is ALZN's forecast return on equity (ROE) for 2026-2026?
(NASDAQ: ALZN) forecast ROE is -323.2%, which is considered weak.
What is ALZN's Price Target?
According to 1 Wall Street analyst that have issued a 1 year ALZN price target, the average ALZN price target is $20.00, with the highest ALZN stock price forecast at $20.00 and the lowest ALZN stock price forecast at $20.00.
The Wall Street analyst predicted that Alzamend Neuro's share price could reach $20.00 by Mar 17, 2026. The average Alzamend Neuro stock price prediction forecasts a potential upside of 2,930.3% from the current ALZN share price of $0.66.
What is ALZN's Earnings Per Share (EPS) forecast for 2026-2026?
(NASDAQ: ALZN) Alzamend Neuro's current Earnings Per Share (EPS) is -$3.04. In 2026, ALZN's EPS is forecast to hit -$1.69 (min: -$1.69, max: -$1.69).
What is ALZN's forecast return on assets (ROA) for 2026-2026?
(NASDAQ: ALZN) forecast ROA is -267.02%, which is lower than the forecast US Biotechnology industry average of 932.61%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.